FDA's April 2026 GLP-1 compounding clarification: what it says and what it means

The FDA's April 2026 statement confirmed the following for 503A compounders:

A compounded drug product that combines semaglutide with another ingredient — such as vitamin B12 (cyanocobalamin) — may be considered "essentially a copy" of a commercially available product when:

• the compounded product is administered by the same route (e.g., injectable)
• the amounts of semaglutide and vitamin B12 in the compounded product are within 10% of the strengths in respective commercially available products

In plain English: if a pharmacy is compounding semaglutide+B12 injections at concentrations close to branded Wegovy and commercial B12 products, that combination is likely to be treated as an essentially copy — even though the specific combination isn't itself FDA-approved.

The FDA's enforcement threshold: four or fewer prescriptions of such combinations per calendar month before the agency would consider the compounder to be producing essentially-copy products "regularly or in inordinate amounts."

The "essentially a copy" restriction is longstanding under 503A — it isn't new to April 2026. What the April clarification did was explicitly apply it to the semaglutide+B12 combination, addressing a common compounding pharmacy argument that adding B12 was sufficient to differentiate the product from approved drugs.

The FDA's position: adding an ingredient doesn't automatically create a clinically significant difference. Unless the prescriber has documented a specific medical reason why the compounded combination is necessary for an identified individual patient, the added ingredient doesn't exempt the product from essentially-copy restrictions.

Semaglutide+B12 formulations became popular in telehealth-adjacent compounding partly because B12 was marketed as addressing common GLP-1 side effects like nausea. The April 2026 clarification signals the FDA's view that this formulation strategy doesn't change the regulatory analysis.

503A pharmacies (traditional pharmacies and physician offices): Can compound for individual patients with a valid prescription. Subject to the essentially-copy restrictions and the four-prescription-per-month enforcement threshold for semaglutide+B12 combinations. Can still compound other formulations if the prescriber documents a patient-specific clinical need for a modification that constitutes a significant difference.

503B outsourcing facilities: Cannot compound semaglutide or tirzepatide because neither drug appears on the 503B Bulks List, and neither is on the FDA Drug Shortages List. 503B facilities produce drugs without patient-specific prescriptions; essentially-copy restrictions are more stringent than under 503A.

If you are getting compounded semaglutide — especially with B12 or another additive — ask your pharmacy directly: does your current formulation comply with the April 2026 FDA clarification?

If your pharmacy is dispensing more than four prescriptions per month of essentially-copy semaglutide+B12 combinations, it may be operating outside of FDA enforcement tolerance. This doesn't automatically make your individual prescription illegal — the exact application depends on specific facts — but it is a risk worth understanding before your next refill.

More important: do not stop your GLP-1 medication abruptly based on this news. Weight regain after discontinuation begins quickly. Any change to your treatment plan should happen in conversation with your prescriber, with a plan in place.

The April 2026 clarification does not resolve every legal question. Ongoing litigation in this space — including Outsourcing Facilities Association v. FDA and related cases — has previously affected FDA enforcement timing. Whether additional legal challenges could modify the enforcement of the April 2026 clarification is not addressed in the FDA's published statement.

Compounders who argue their specific formulation contains a significant difference from commercially available products may continue operating under that exception, with legal risk that is theirs to bear.

• Does my current compounded formulation comply with FDA guidelines under the April 2026 clarification?
• If my compounded GLP-1 access ends, what branded options are available and covered under my insurance?
• If I need to transition from a compounded to a branded product, how do we manage that medically?
• What happens to my weight management plan if there's a gap in access?

• Whether your pharmacy notifies you of any changes to your formulation or supply
• FDA enforcement actions regarding compounded GLP-1s, published on FDA.gov
• Court rulings in ongoing litigation involving the compounding industry and FDA

If you're on a compounded GLP-1 with B12 or other additives, ask your pharmacy whether your formulation still complies with FDA guidelines — before your next refill.

fda.gov

fda.gov